Anna-Lena Engwall has been appointed head of AstraZeneca’s Nordic-Baltics marketing company and she started her new position February 6 2020.
Anna Lena Engwall has long experience from the pharma and biotech industry and she has held a number of different managing positions at companies like Novartis and Shire. She has also been a member of the Board at the industry association LIF. Most recently she has been the Head of Nordic/Baltics at Shire.
“The Nordic and the Baltics are very important markets for AstraZeneca and we are convinced that Anna-Lena, with her strong leadership experience and knowledge within pharmaceuticals and biotechnology, will lead our innovative team towards new successes,” says Iskra Reic, Executive Vice President Europe and Canada, AstraZeneca.
“I can contribute with value to patients and society”
Anna-Lena Engwall is a licensed nurse and she also holds a degree within marketing and business economics. She has replaced Michelle Werner, who recently started a new global position within AstraZeneca’s oncology business.
“I am tremendously proud to undertake this new role at AstraZeneca. What applied to me is that I can contribute with value to patients and society by working at a company which so clearly focuses on moving innovation and research forward when it comes to neglected diseases. Besides the strong research portfolio the company’s sustainability focus impresses me, not least the promise of eliminating emissions and to become carbon dioxide negative 2030,” says Anna-Lena Engwall.
